Aegerion Pharmaceuticals said today that the FDA had approved lomitapide (Juxtapid) to help further lower cholesterol in patients with homozygous familial hypercholesterolemia. The approval comes with ...

Please provide your email address to receive an email when new articles are posted on . Lomitapide was approved for treatment of homozygous familial hypercholesterolemia in children as young as 2 ...

Evinacumab is highlighted as a new therapy for treating patients with homozygous FH. Eliot Brinton, MD: There has been a recent breakthrough in HoFH [homozygous familial hypercholesterolemia] ...

Are you taking Lomitapide? Are you aware of the dangers of combining Lomitapide with certain foods, herbs, or alcohol? Drug-food-interactions are seldom discussed but can lead to undesirable side ...

A total of 46 pediatric patients were enrolled, with 43 patients completing the run-in phase and entering the efficacy phase. 20 patients were between 5 and 10 years of age. 23 patients were between ...

PARMA, Italy, March 30, 2026 (GLOBE NEWSWIRE)-- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare ...

The FDA has approved lomitapide (Aegerion Pharmaceuticals, Cambridge, MA) as an adjunct to a low-fat diet and other lipid-lowering drugs, with or without LDL apheresis, to reduce LDL-C, total ...

Discover comprehensive details about Lomitapide, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

The APH-19 trial enrolled a total of 46 patients 5 to 17 years of age with HoFH who had a mean LDL-C at baseline of 436 mg/dL. Lomitapide was associated with statistically significant reductions in ...

Lomitapide (trade name: Lojuxta) has been available since July 2013 as additional treatment for adults with homozygous familial hypercholesterolaemia in whom diet and other drugs do not sufficiently ...

London, UK - The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that the lomitapide preparation Lojuxta (Aegerion Pharmaceuticals) be ...